Aura Biosciences, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Aura Biosciences, Inc. (AURA) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 25.52 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-11
- Aura Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 18.65M shares, a 99.81% increase year-over-year.
- Aura Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 9.33M shares, a 21.83% increase year-over-year.
- Aura Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 7.66M shares, a 40.03% increase year-over-year.
- Aura Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 5.47M shares, a 20.94% increase year-over-year.
- Aura Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 16.56M shares, a 132.40% increase from fiscal 2024.
- Aura Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 7.12M shares, a 16.09% increase from fiscal 2023.
- Aura Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 6.14M shares, a 37.28% increase from fiscal 2022.
- Aura Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 4.47M shares, a 0.17% decline from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 25.52M shares 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | 18.65M shares 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | 16.56M shares 10-K · filed 2026-03-30 | |||
| 2025-09-30 | 13.11M shares 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | 13.51M shares 10-Q · filed 2026-08-11 | |||
| 2025-03-31 | 9.33M shares 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | 7.12M shares 10-K · filed 2026-03-30 | |||
| 2024-09-30 | 7.40M shares 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | 7.82M shares 10-Q · filed 2025-08-13 | |||
| 2024-03-31 | 7.66M shares 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | 6.14M shares 10-K · filed 2025-03-24 | |||
| 2023-09-30 | 5.60M shares 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | 5.28M shares 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | 5.47M shares 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | 4.47M shares 10-K · filed 2024-03-27 | |||
| 2022-09-30 | 4.47M shares 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | 4.35M shares 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | 4.52M shares 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | 4.48M shares 10-K · filed 2023-03-15 | |||
| 2021-09-30 | 25.73M shares 10-Q · filed 2021-11-24 | 25.73M shares 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | 25.47M shares 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | 23.98M shares 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | 15.84M shares 10-K · filed 2022-03-23 | |||
| 2020-09-30 | 14.69M shares 10-Q · filed 2021-11-24 | 14.69M shares 10-Q · filed 2021-11-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |